2024
The Impact of Active Ascertainment on Sex-Specific Differences in the Prevalence and Phenotype of Transthyretin Cardiac Amyloidosis: The SCAN-MP Study
Chan N, Einstein A, Teruya S, Rodriguez C, Helmke S, Cuomo M, Santana D, Castillo M, Smiley D, Sabogal N, Lamour S, Winburn M, Fine D, de Freitas C, Kattan C, Miller E, Maurer M, Ruberg F. The Impact of Active Ascertainment on Sex-Specific Differences in the Prevalence and Phenotype of Transthyretin Cardiac Amyloidosis: The SCAN-MP Study. The American Journal Of Cardiology 2024 PMID: 39581521, DOI: 10.1016/j.amjcard.2024.11.019.Peer-Reviewed Original ResearchATTR-CATransthyretin cardiac amyloidosisProportion of womenCardiac amyloidosisReferral cohortLower left ventricular mass indexHigher left ventricular ejection fractionPrevalence of ATTR-CAATTR-CA patientsWild-type diseaseVentricular ejection fractionVentricular mass indexPosterior wall thicknessAscertainment cohortLeft ventricular hypertrophyReduce sex disparitiesHigher proportion of womenATTRwt-CAEjection fractionEchocardiographic evidenceHeart failureMass indexSex-specific differencesSevere phenotypeSex distributionFrom transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics
Walenczyk K, Singh A, Tong K, Burg M, Miller E. From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics. American Journal Of Health-System Pharmacy 2024, zxae183. PMID: 38963826, DOI: 10.1093/ajhp/zxae183.Peer-Reviewed Original ResearchPatient sociodemographic characteristicsATTR-CASociodemographic characteristicsSpecialty pharmacyPyrophosphate scintigraphyPopulation prevalence ratesEconomically disadvantaged areasTransthyretin cardiac amyloidosisBlack/African American raceReduce disparitiesPotential patient subgroupsPharmacy processesProportion of daysClinical pathwayCompare sociodemographicsDisadvantaged areasEquitable provisionTafamidis therapyCardiac amyloidosisTafamidis treatmentPrevalence ratesClinical programsAmerican racePatient subgroupsPosting manuscriptsReproducibility for quantification of myocardial Tc-99m PYP amyloid uptake in grade 1 patients
Sandoval V, Goyal D, Miller E, Liu Y. Reproducibility for quantification of myocardial Tc-99m PYP amyloid uptake in grade 1 patients. European Heart Journal - Cardiovascular Imaging 2024, 25: jeae142.047. DOI: 10.1093/ehjci/jeae142.047.Peer-Reviewed Original ResearchStandardized uptake valueTc-99m PYP uptakeTc-99Cardiac amyloidosisHeart failureStandard uptake value quantificationStandardized uptake value calculationSPECT imagesIntractable heart failureSystolic heart failureIntroduction of therapyPlanar imagingTc-99m pyrophosphateAmyloid patientsSPECT/CT imagingInter-reproducibilityUptake valueContralateral ratioCoefficient of variationDisease progressionH/M ratioGrade 1Blood poolPatientsH/CL ratio
2023
Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases.
Chan N, Einstein A, Griffin J, Rosenblum H, Teruya S, Cuomo M, De Los Santos J, DeLuca A, Johnson L, Kinkhabwala M, Leb J, Mintz A, Fine D, Helmke S, Muralidhar V, Pandey S, Sabogal N, Saith S, Winburn M, Smiley D, Miller E, Ruberg F, Maurer M. Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases. Journal Of Nuclear Cardiology 2023, 30: 2531-2539. PMID: 38245059, DOI: 10.1007/s12350-023-03310-7.Peer-Reviewed Original ResearchConceptsTc-99m PYP uptakeExtracardiac uptakeATTR-CACardiac amyloidosisClinically actionable findingsDiagnose transthyretin cardiac amyloidosisTc-99Transthyretin cardiac amyloidosisBone uptakeTime of scanningBreast uptakeTc-99m PYP imagingThyroid uptakeHeart failureBlack raceRenal uptakeNuclear imagingPyrophosphate imagingTechnetium pyrophosphateHispanic ethnicityHispanic participantsNuclear scintigraphyMinority populationsClinicSelf-identifyPrevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases
Chan N, Einstein A, Griffin J, Rosenblum H, Teruya S, Cuomo M, De Los Santos J, DeLuca A, Johnson L, Kinkhabwala M, Leb J, Mintz A, Fine D, Helmke S, Muralidhar V, Pandey S, Sabogal N, Saith S, Winburn M, Smiley D, Miller E, Ruberg F, Maurer M. Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases. Journal Of Nuclear Cardiology 2023, 30: 2531-2539. PMID: 37311914, DOI: 10.1007/s12350-023-03310-7.Peer-Reviewed Original ResearchConceptsExtracardiac uptakePYP uptakeCardiac amyloidosisBone uptakeActionable findingsTiming of scansTransthyretin cardiac amyloidosisHeart failureBreast uptakeMean ageBlack raceRenal uptakeHispanic ethnicityThyroid uptakeATTR-CANuclear scintigraphyHispanic participantsTechnetium pyrophosphateNuclear imagingPYP scanPopulation studiesSelf-identified BlackAdditional testingAmyloidosisSubjectsDesign and Rationale the SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study
Ruberg F, Blaner W, Chiuzan C, Connors L, Einstein A, Fine D, Helmke S, Kurian D, Pandey S, Raiszadeh F, Rodriguez C, Sabogal N, Teruya S, Winburn M, Chung W, Cohn E, Miller E, Kelly J, Maurer M. Design and Rationale the SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study. Journal Of The American Heart Association 2023, 12: e028534. PMID: 37066788, PMCID: PMC10227254, DOI: 10.1161/jaha.122.028534.Peer-Reviewed Original ResearchConceptsATTR-CMHeart failureHealth/National HeartOlder black patientsYears of ageCaribbean Hispanic patientsDeposition of transthyretinNoninvasive nuclear imagingBlack patientsHispanic patientsProspective studyBlood InstituteSelf-identified Black individualsNational HeartCardiac amyloidosisUS FoodImportant causeSecondary objectiveOlder individualsSubstitution of valineHispanic individualsNuclear imagingNational InstituteBlack individualsPatientsThe Association Between Body Mass Index And Functional Status In Minority Patients With Heart Failure With Preserved Ejection Fraction: The SCAN-MP Study
Driggin E, Rosenblum H, Teruya S, Rodriguez C, Kurian D, Raiszadeh F, Fine D, Sabogal N, Edmiston J, Massillon D, Winburn M, Miller E, Ruberg F, Maurer M. The Association Between Body Mass Index And Functional Status In Minority Patients With Heart Failure With Preserved Ejection Fraction: The SCAN-MP Study. Journal Of Cardiac Failure 2023, 29: 668-669. DOI: 10.1016/j.cardfail.2022.10.299.Peer-Reviewed Original ResearchBody mass indexKCCQ overall summary scoreExcess fat massFunctional statusOverall summary scoreObesity statusQuality of lifeMinority patientsFunctional capacityObese patientsEjection fractionHeart failureIndependent predictorsMass indexSPPB scoreFat massCardiac amyloidosisSummary scoresMuscle massShort Physical Performance Battery scoreFirst heart failure hospitalizationMedian body mass indexPhysical Performance Battery scoreHigher body mass indexWorse SPPB scoreDiagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc99m pyrophosphate (PYP) imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: the SCAN-MP study
Pandey S, Teruya S, Rodriguez C, Deluca A, Kinkhabwala M, Johnson L, Fine D, Sabogal N, Winburn M, Castillo M, Bhatia K, Malkovskaya R, Raiszadeh F, Kurian D, Miller E, Einstein A, Maurer M, Ruberg F. Diagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc99m pyrophosphate (PYP) imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: the SCAN-MP study. Journal Of Nuclear Cardiology 2023, 30: 1414-1419. PMID: 36823486, PMCID: PMC11268194, DOI: 10.1007/s12350-023-03203-9.Peer-Reviewed Original ResearchConceptsTransthyretin cardiac amyloidosisATTR-CACardiac amyloidosisLow pretest probabilityLow pretest likelihoodLV wall thicknessDiagnostic performance characteristicsPositive predictive valueNon-invasive diagnosisConclusionAmong patientsMinority older adultsHeart failurePretest likelihoodPretest probabilitySemi-quantitative parametersPYP uptakeImportant misclassificationPredictive valueImaging thresholdsOptimal heartOlder adultsDiagnostic performancePatientsReference standardScans
2020
Survival Following Implantable Cardioverter‐Defibrillator Implantation in Patients With Amyloid Cardiomyopathy
Higgins AY, Annapureddy AR, Wang Y, Minges KE, Lampert R, Rosenfeld LE, Jacoby DL, Curtis JP, Miller EJ, Freeman JV. Survival Following Implantable Cardioverter‐Defibrillator Implantation in Patients With Amyloid Cardiomyopathy. Journal Of The American Heart Association 2020, 9: e016038. PMID: 32867553, PMCID: PMC7726970, DOI: 10.1161/jaha.120.016038.Peer-Reviewed Original ResearchConceptsImplantable cardioverter defibrillator implantationCardioverter-defibrillator implantationNonischemic cardiomyopathyCardiac amyloidosisDiabetes mellitusCerebrovascular diseaseVentricular tachycardiaMultivariable Cox proportional hazards regression modelsCox proportional hazards regression modelProportional hazards regression modelsKaplan-Meier survival curvesCox proportional hazards modelPropensity-matched cohortOutcomes of patientsHazards regression modelsProportional hazards modelCause mortalityICD implantationRenal functionMultivariable analysisConclusions MortalityRisk factorsRegistry dataAmyloid cardiomyopathyHigh riskAdvances in PET-Based Cardiac Amyloid Radiotracers
Gallegos C, Miller EJ. Advances in PET-Based Cardiac Amyloid Radiotracers. Current Cardiology Reports 2020, 22: 40. PMID: 32430600, DOI: 10.1007/s11886-020-01284-3.Peer-Reviewed Original ResearchConceptsPositron emission tomographyCardiac amyloidosisAmyloid depositionAmyloid radiotracersCardiac amyloid depositionCare of patientsTransthyretin cardiac amyloidosisCardiac imaging techniquesCongo red stainingPurpose of ReviewWeNovel positron emission tomographyEndomyocardial biopsyImaging featuresAmyloid depositsUnmet needInvasive methodEmission tomographyAmyloidosisGold standardAdditive valueRed stainingBiopsyFurther dataDiagnosisRecent studies
2019
SURVIVAL FOLLOWING IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR IMPLANTATION IN PATIENTS WITH CARDIAC AMYLOIDOSIS
Higgins A, Annapureddy A, Wang Y, Minges K, Lampert R, Rosenfeld L, Jacoby D, Curtis J, Miller E, Freeman J. SURVIVAL FOLLOWING IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR IMPLANTATION IN PATIENTS WITH CARDIAC AMYLOIDOSIS. Journal Of The American College Of Cardiology 2019, 73: 694. DOI: 10.1016/s0735-1097(19)31302-6.Peer-Reviewed Original Research
2018
Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis
Papoutsidakis N, Miller EJ, Rodonski A, Jacoby D. Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis. Journal Of Cardiac Failure 2018, 24: 131-133. PMID: 29305186, DOI: 10.1016/j.cardfail.2017.12.005.Peer-Reviewed Original Research
2016
Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis
Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, Seldin DC, Ruberg FL. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. European Heart Journal - Cardiovascular Imaging 2016, 18: 1057-1064. PMID: 27965280, DOI: 10.1093/ehjci/jew298.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkersBortezomibBostonCardiomyopathiesCohort StudiesEchocardiography, Doppler, ColorFemaleFollow-Up StudiesHeart Function TestsHospitals, UniversityHumansImmunoglobulin Light-chain AmyloidosisKaplan-Meier EstimateMaleMelphalanMiddle AgedPrognosisRetrospective StudiesROC CurveSensitivity and SpecificitySurvival AnalysisTreatment OutcomeVentricular Dysfunction, LeftConceptsB-type natriuretic peptideFree light chainsLight-chain cardiac amyloidosisCardiac amyloidosisCardiac biomarkersCR groupGlobal LSHigh-dose melphalanLongitudinal systolic strainSerum free light chainsCardiac functional impairmentCardiac functional improvementStandard echocardiographic measuresCardiac function improvementShort-term improvementBNP reductionComplete responseDiastolic functionEchocardiographic measuresHematologic responseNatriuretic peptideSystolic strainFunctional improvementFunction improvementFunctional impairmentMulticenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis
Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, Pozniakoff T, Ruberg FL, Miller EJ, Berk JL, Dispenzieri A, Grogan M, Johnson G, Bokhari S, Maurer MS. Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. JAMA Cardiology 2016, 1: 880-889. PMID: 27557400, DOI: 10.1001/jamacardio.2016.2839.Peer-Reviewed Original ResearchConceptsATTR cardiac amyloidosisCardiac amyloidosisMulticenter studyWorse survivalEjection fractionHeart failureCardiac imagingMultivariable Cox proportional hazards regression analysisCox proportional hazards regression analysisProportional hazards regression analysisRetrospective cohort studyHigh clinical suspicionSingle-center studyHazards regression analysisKaplan-Meier analysisAL cardiac amyloidosisDifferentiation of patientsTransthyretin cardiac amyloidosisDates of analysisSemiquantitative visual scoreContralateral chestPlanar technetiumClinical suspicionCohort studyPrognostic importanceNonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation 2016, 133: 2404-2412. PMID: 27143678, DOI: 10.1161/circulationaha.116.021612.Peer-Reviewed Original ResearchConceptsCardiac ATTR amyloidosisBone scintigraphyCardiac transthyretin amyloidosisATTR amyloidosisMyocardial radiotracer uptakeRadiotracer uptakeTransthyretin amyloidosisMajority of patientsCardiac AL amyloidosisNoninvasive diagnostic criteriaMyocardial amyloid depositsPositive predictive valueHistological confirmationMulticenter studySpecialist centresMonoclonal gammopathyCardiac amyloidosisPromising therapyAL amyloidosisATTR amyloidDiagnostic criteriaAmyloid depositsFatal cardiomyopathyPatientsScintigraphyNational patterns in imaging utilization for diagnosis of cardiac amyloidosis: A focus on Tc99m-pyrophosphate scintigraphy
Harb SC, Haq M, Flood K, Guerrieri A, Passerell W, Jaber WA, Miller EJ. National patterns in imaging utilization for diagnosis of cardiac amyloidosis: A focus on Tc99m-pyrophosphate scintigraphy. Journal Of Nuclear Cardiology 2016, 24: 1094-1097. PMID: 27016106, DOI: 10.1007/s12350-016-0478-3.Peer-Reviewed Original ResearchConceptsCardiac amyloidosisCA diagnosisContralateral lung ratioTransthyretin cardiac amyloidosisLung ratioDiagnostic modalitiesMost centersTest utilizationWeb-based surveyScintigraphyMultiple centersDiagnosisQuantification of uptakeLow penetranceNational surveyAmyloidosisNational patternsCardiologistsDose